| __timestamp | BioCryst Pharmaceuticals, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 9216000000 |
| Thursday, January 1, 2015 | 1896000 | 8296000000 |
| Friday, January 1, 2016 | 2699000 | 10044000000 |
| Sunday, January 1, 2017 | 1702000 | 11560000000 |
| Monday, January 1, 2018 | 471000 | 10558000000 |
| Tuesday, January 1, 2019 | 4101000 | 9351000000 |
| Wednesday, January 1, 2020 | 1676000 | 8933000000 |
| Friday, January 1, 2021 | 7264000 | 8284000000 |
| Saturday, January 1, 2022 | 6594000 | 7952000000 |
| Sunday, January 1, 2023 | 4661000 | 8200000000 |
| Monday, January 1, 2024 | 8480000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, cost efficiency is a critical metric for success. This analysis compares the cost of revenue efficiency between Teva Pharmaceutical Industries Limited and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Teva, a global leader, consistently reported a cost of revenue exceeding $8 billion annually, peaking in 2017 at approximately $11.56 billion. In contrast, BioCryst, a smaller player, showed a more volatile trend, with costs ranging from $122,000 in 2014 to a high of $7.26 million in 2021. Despite the vast difference in scale, BioCryst's cost efficiency improved significantly, with a 3,700% increase from 2014 to 2021. Meanwhile, Teva's costs decreased by about 31% from their peak. This data highlights the contrasting strategies and market positions of these two companies, offering insights into their operational efficiencies and market dynamics.
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Amgen Inc. and Teva Pharmaceutical Industries Limited's Expenses
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Teva Pharmaceutical Industries Limited
Cost of Revenue Trends: Teva Pharmaceutical Industries Limited vs Ionis Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and ADMA Biologics, Inc.
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Teva Pharmaceutical Industries Limited and Viridian Therapeutics, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Amneal Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: PTC Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Comparison: Mesoblast Limited vs BioCryst Pharmaceuticals, Inc.
Dyne Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored